How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Venous Diseases Treatment Market
- By Treatment Type: Sclerotherapy, Endovenous Laser Therapy (EVLT), Radiofrequency Ablation (RFA), Surgical Ligation and Stripping, Foam Sclerotherapy
- By Disease Type: Varicose Veins, Deep Vein Thrombosis (DVT), Chronic Venous Insufficiency (CVI), Venous Ulcers, Superficial Thrombophlebitis
- By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Pharmacies, Home Healthcare Settings
- By Product Type: Compression Stockings, Venous Stents, Pharmaceuticals (Anticoagulants, Venoactive Drugs), Medical Devices (Catheters, Laser Devices), Sclerosing Agents
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Sclerotherapy leads By Treatment Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 18 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 289 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 18 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Venous Diseases Treatment Market report
A complete, evidence-based study - 11 chapters and 121 sections covering market size, segmentation across 4 axes, regional analysis and 18 company profiles, forecast to 2033.
Segmentation covered
Treatment Type 5
Disease Type 5
End User 5
Product Type 5
Companies profiled
Medtronic plc
Boston Scientific Corporation
Becton
Dickinson and Company (BD)
Cook Medical
AngioDynamics Inc.
Terumo Corporation
C.R. Bard
Inc. (now part of BD)
Veniti Inc.
Siemens Healthineers
Philips Healthcare
+6 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
18 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Medtronic plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Boston Scientific Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Becton
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Dickinson and Company (BD)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Cook Medical
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →AngioDynamics Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Terumo Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →C.R. Bard
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Inc. (now part of BD)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Veniti Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Siemens Healthineers
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Philips Healthcare
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Smith & Nephew plc
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →Biolitec AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.232 →Venous Medical Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Venclose Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Venous Solutions
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.256 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$3,153M by 2033 · 5.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Sclerotherapy28.1
- Endovenous Laser Therapy (EVLT)20.1
- Radiofrequency Ablation (RFA)9.1
- Surgical Ligation and Stripping21.8
- Foam Sclerotherapy20.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$681.2M → $1,024M · 5.2%
Europe$474.8M → $651.2M · 4.0%
Asia Pacific$433.5M → $663.3M · 5.5%
Latin America$268.4M → $395.9M · 5.0%
Middle East and Africa$206.4M → $352.9M · 6.9%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.382026
5.392027
5.422028
5.432029
5.442030
5.452031
5.472032
5.482033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Medtronic plc19.2
- Boston Scientific Corporation21.8
- Becton8.9
- Dickinson and Company (BD)7.0
- Cook Medical5.5
- AngioDynamics Inc.9.7
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Treatment Type32.2%
Disease Type27.2%
End User25.1%
Product Type15.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.2
- Europe21.1
- Asia Pacific21.5
- Latin America12.8
- Middle East and Africa11.4
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Medtronic plc | 97 | 98 | 78 | 97 | 79 | 82 | 89 |
| Boston Scientific Corporation | 92 | 70 | 91 | 74 | 76 | 84 | 81 |
| Becton | 79 | 83 | 83 | 66 | 86 | 65 | 77 |
| Dickinson and Company (BD) | 79 | 78 | 70 | 79 | 81 | 60 | 75 |
| Cook Medical | 71 | 64 | 73 | 73 | 58 | 70 | 68 |
| AngioDynamics Inc. | 56 | 57 | 67 | 60 | 64 | 65 | 62 |
| Terumo Corporation | 53 | 61 | 52 | 55 | 61 | 51 | 56 |
| C.R. Bard | 38 | 44 | 48 | 57 | 43 | 54 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Medtronic plc
- Boston Scientific Corporation
- Becton
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Medtronic plc | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Boston Scientific Corporation | ✓ | ◐ | ✓ | ◐ | ◐ | ✓ |
| Becton | ✓ | ◐ | ✓ | ◐ | ✓ | ◐ |
| Dickinson and Company (BD) | ✓ | ✓ | ✓ | ◐ | ✓ | ◐ |
| Cook Medical | ✓ | ◐ | ✓ | ✓ | − | ✓ |
| AngioDynamics Inc. | ◐ | ◐ | − | ◐ | − | − |
| Terumo Corporation | − | ◐ | − | − | ◐ | − |
| C.R. Bard | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Medtronic plc89
2Boston Scientific Corporation81
3Becton77
4Dickinson and Company (BD)75
5Cook Medical68
6AngioDynamics Inc.62
7Terumo Corporation56
8C.R. Bard47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Medtronic plcBoston Scientific Corporation
Challenger3
Strong scale, closing on the leaders.
BectonDickinson and Company (BD)Cook Medical
Contender1
Focused players with pockets of strength.
AngioDynamics Inc.
Niche2
Specialists in a single segment or region.
Terumo CorporationC.R. Bard
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Treatment Type in North America, then scale across Venous Diseases Treatment Market — a $368M beachhead inside a $5.86B market.
Beachhead (SOM)$368Mobtainable near-term
Serviceable (SAM)$2.13Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Sclerotherapy
Best fit — highest urgency & budget in Treatment Type.
Economic buyer76 fit
Endovenous Laser Therapy (EVLT)
Strong fit — clear ROI and a fast path to value.
End user68 fit
Radiofrequency Ablation (RFA)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Treatment Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Disease Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales46%
Partner / channel26%
Digital / self-serve20%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Treatment Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Venous Diseases Treatment Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified23%
Evaluation14%
Closed-won5%
$10.0KCAC
$38KLTV
3.8:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Venous Diseases Treatment Market is a durable-growth opportunity — $8.63B by 2033, compounding at 8.6%.
TAM · 2025$4.46Btoday
TAM · 2033$8.63Bforecast
CAGR8.6%2027–2033
Cumulative$57.1Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$8.63BTotal addressable market
SAM$3.21BServiceable available market
SOM$550MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.6% CAGR
Demand compounds through 2033, outpacing GDP across Treatment Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Treatment Type moving from early to mainstream — durable secular demand.
Consolidation upside
18+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$8.63BLarge & growingTAM by 2033 at 8.6% CAGR
$3.21BServiceable nowreachable with today’s model
$550MBeachhead winobtainable near-term share
18+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$6.73BBear5.6% CAGR
$8.63BBase8.6% CAGR
$11.1BBull11.4% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Disease Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Venous Diseases Treatment Market — a $5.90B market by 2033. Plan: grow share from 8.9% to 14.5%.
Market size · 2033$5.90Btotal addressable
Market CAGR5.1%2027–2033
Target share14.5%from 8.9% today
Revenue ambition$856Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.9% | 14.5% | At risk |
| Revenue | $530M | $856M | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Ahead |
| Gross margin | 33.5% | 41.6% | On track |
| Customer retention | 88.1% | 93.2% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Treatment Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Disease Type capability
A defensible second engine — invest in Disease Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Treatment Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Disease Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $109M capacity & capability investment
- Greenlight bolt-on M&A in Disease Type
- Authorise North America expansion plan
- Fund R&D program for Treatment Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeBehind
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Venous Diseases Treatment Market conversation — a $9.65B market you can size, segment and defend in minutes.
Market size · 2033$9.65Btotal opportunity
Growth10.6%CAGR to 2033
Addressable buyers1,246+accounts in scope
Typical ROI5.6×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Treatment Type
Goal Grow share in Treatment Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.6×return on cost, year one
< 4 mopayback period
$65K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
18+players profiled in this market
Coverage includes
Medtronic plcBoston Scientific CorporationBectonDickinson and Company (BD)Cook MedicalAngioDynamics Inc.Terumo CorporationC.R. Bard+10 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Venous Diseases Treatment Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Venous Diseases Treatment Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Venous Device Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportVenous Blood Collection Needle Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportVenom Antiserum Market
Market size, share, segmentation and regional forecast.
$538M market · 2025 base year
View reportVenlafaxine HCL Market
Market size, share, segmentation and regional forecast.
$5.3B market · 2025 base year
View reportVenlafaxine HCL API Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportVenlafaxine API Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportVenipuncture Syring Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportVenipuncture Needle Market
Market size, share, segmentation and regional forecast.
$766M market · 2025 base year
View reportVenetoclax API Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportVendor Neutral Archive (VNA) Software Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportVendor Neutral Archive and PACS Market
Market size, share, segmentation and regional forecast.
$4.7B market · 2025 base year
View reportVemurafenib Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.